Treatment Compliance in Children and Adolescents on ADHD Medication
Overview
The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine clinical setting. Compliance will be assessed using the Pediatric Compliance Self-Rating (PCSR) Instrument. A patient will be considered as compliant at a given visit, if the PCSR score is at least 5, corresponding to taking the medication at least often.
Full Title of Study: “Treatment Adherence and Compliance in Children and Adolescents on ADHD Medication and Emotional Expression in Clinical Practice”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
Interventions
- Drug: Atomoxetine
- in-label use
- Drug: stimulants (any approved ADHD medication)
- in-label use
Arms, Groups and Cohorts
- A
- A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
- B
- B: ADHD-patients receiving stimulants
Participating in This Clinical Trial
Inclusion Criteria
- 6-17 years old – diagnosis of ADHD according to ICD-10 or DSM-IV criteria – new initiation onto an approved medication to treat ADHD Exclusion Criteria:
- no specific exclusion criteria
Gender Eligibility: All
Minimum Age: 6 Years
Maximum Age: 17 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Eli Lilly and Company
- Overall Official(s)
- Call 1-877-CTLILLY (1-877-615-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), Study Director, Eli Lilly and Company
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.